10x Genomics
396 hedge funds and large institutions have $4.92B invested in 10x Genomics in 2026 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 98 increasing their positions, 143 reducing their positions, and 33 closing their positions.
421% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $5.14M
206% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 33
28% more capital inflows, than outflows
Capital inflows: $510M | Capital outflows: $399M
19% more funds holding
Funds holding: 334 → 396 (+62)
3.48% more ownership
Funds ownership: 106.46% → 109.94% (+3.5%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
31% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 143
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$115M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$53.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$48.6M |
| 4 |
Anomaly Capital Management
New York
|
+$22.7M |
| 5 |
Jane Street
New York
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$51.1M |
| 2 |
ARK Investment Management
St. Petersburg,
Florida
|
-$44.9M |
| 3 |
Casdin Capital
New York
|
-$32.1M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$24M |
| 5 |
Nikko Asset Management Americas
New York
|
-$23.9M |
TXG Hedge Fund Activity: Q2 2026 in Review
396 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q2 2026, worth a combined $4.92B — up 85% from $2.66B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new TXG positions and 33 closed out — a net gain of 68 holders — while 98 added to existing stakes and 143 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $115M. The largest seller was Millennium Management, cutting an estimated $51.1M.
- 396 institutional investors held 10x Genomics (TXG) as of Q2 2026, up from 334 in Q1 2026.
- Funds reported $4.92B of 10x Genomics stock for Q2 2026, up 85% quarter-over-quarter.
- 101 funds opened new 10x Genomics positions in Q2 2026 and 33 closed out, a net change of +68 holders.
- The largest 10x Genomics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $115M added.
- The largest 10x Genomics seller in Q2 2026 was Millennium Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q2 2026.